Commodore Capital
$1.7B 13F equity value
41 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Commodore Capital covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| RLAY | RELAY THERAPEUTICS INC | 12,000,000 | $225M | 13.4% |
| ELVN | ENLIVEN THERAPEUTICS INC | 3,275,000 | $166M | 9.9% |
| ALKS | ALKERMES PLC | 3,000,000 | $157M | 9.4% |
| COGT | COGENT BIOSCIENCES INC | 3,050,000 | $118M | 7.0% |
| AMLX | AMYLYX PHARMACEUTICALS INC | 5,650,000 | $101M | 6.0% |
| DFTX | DEFINIUM THERAPEUTICS INC | 2,000,000 | $94M | 5.6% |
| SYRE | SPYRE THERAPEUTICS INC | 846,786 | $75M | 4.5% |
| ANRO | ALTO NEUROSCIENCE INC | 2,723,196 | $72M | 4.3% |
| TNGX | TANGO THERAPEUTICS INC | 2,250,000 | $70M | 4.2% |
| EYPT | EYEPOINT INC | 4,600,000 | $66M | 3.9% |
Track Commodore Capital's 13F portfolio: $1.7B in reported holdings, 41 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}